Investor Presentaiton

REVENUE Operating revenue up 19.2% to $215.1m, reflecting both organic growth and the X-Ray Group, Peloton Radiology and Horizon Radiology acquisitions • . . • Revenue growth of $34.6m, including the X-Ray Group ($5.1m for four months from July to October 2022 following completion of the acquisition in November 2021), Peloton Radiology $18.1m and Horizon Radiology $5.4m following completion of both these acquisitions on 1 July 2022. Organic operating revenue from all sources (including reporting contracts) in Australia grew 4.1% (Q1 2.0%; Q2 6.2%; January 2023 double digit growth), above the Medicare industry weighted average for the States in which IDX operates being a 1.2% benefits decrease adjusted for working days. Note further that IDX's growth is off a higher base relative to the industry weighted average for the States in which IDX operates given the more regional nature of IDX's operations which were less impacted by COVID-19 in the prior corresponding period, in particular in Victoria. Average fees per exam (including reporting contracts) in Australia increased by 5.2% in 1H FY23, reflective of an on-going move to the higher end CT, MRI and PET scan modalities and to a lesser extent Medicare indexation of 1.6% applied to 97% of diagnostic imaging services, including MRI, from 1 July 2022, and selective price increases. New Zealand contributed revenue in 1H FY23 of $26.8m (1H FY22 $20.1m) with an organic revenue increase of 4.1% on a constant currency basis adjusted for working days. New Zealand revenues continued to be impacted by referrer-owned radiology practices in Auckland. The company continues to plan and implement management initiatives to address this situation and also work with industry and regulatory authorities to maintain professional, quality, arms-length referral practices that protect patient interests. All revenue presented above is denominated in Australian dollars ($AUD). Kidx

View entire presentation